<DOC>
	<DOCNO>NCT00282295</DOCNO>
	<brief_summary>New immunization recommendation US include vaccination adolescent pertussis meningococcal disease . The Advisory Committee Immunization Practices Centers Disease Control Prevention recommend Tdap ( Tetanus Toxoid , Reduced Diphtheria Toxoid And Acellular Pertussis Vaccine Adsorbed ) MCV4 ( Meningococcal conjugate vaccine serotypes A , C , Y W-135 ) vaccine administer adolescent office visit vaccination vaccine indicate . Therefore , study design evaluate safety immunogenicity booster vaccination Boostrix co-administered Menactra compare administration either vaccine alone healthy adolescent 11 - 18 year age .</brief_summary>
	<brief_title>US-licensed Combined Vaccine Against Tetanus &amp; Diphtheria , Given With US-licensed Vaccine Against Meningococcal Disease</brief_title>
	<detailed_description>A phase IV , randomize , partially blind multicenter study evaluate safety immunogenicity booster vaccination GlaxoSmithKline 's tetanus toxoid , reduce diphtheria toxoid acellular pertussis vaccine , adsorb [ Tdap Boostrix® ] co-administered intramuscularly Aventis-Pasteur 's meningococcal ( serogroups A , C , Y W-135 ) polysaccharide diphtheria toxoid conjugate vaccine ( Menactra™ ) compare administration either vaccine alone healthy adolescent 11-18 year age . `` Experimental design : Prospective , randomize , control multicenter study three group : Group 1 : Boostrix + Menactra Day 0 , blood sample Month 0 Month 1 Group 2 : Boostrix Day 0 , Menactra Month 1 , blood sample Month 0 , Month 1 , Month 2 Group 3 : Menactra Day 0 , Boostrix Month 1 , blood sample Month 0 , Month 1 Month 2 Treatment allocation : randomize 1:1:1 Type study : self-contained Duration study : Approximately one month subject Group 1 approximately two month subject Group 2 Group 3 . ''</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy subject establish medical history historydirected physical examination enter study . Previously complete routine childhood vaccination diphtheria , tetanus pertussis disease accord recommended vaccination schedule time . Females childbearing potential time study entry require negative pregnancy test prior administration dose vaccine require abstinent use adequate contraceptive precaution one month prior vaccination . Subjects also require agree continue precaution two month vaccination . Administration preschool booster DTP vaccine within previous 5 year Administration diphteriatetanus ( Td ) booster within previous 5 year Previous vaccination N. meningitidis Hypersensitivity latex History serious allergic reaction ( e.g . anaphylaxis ) follow tetanus toxoid , diphteria toxoid pertussiscontaining vaccine component study vaccine History encephalopathy ( e.g . coma , decrease level consciousness , prolonged seizure ) within seven day administration previous dose pertussis vaccine taht attributable another identifiable cause Progressive neurologic disorder , uncontrolled epilepsy progressive encephalopathy : pertussis vaccine administer individual condition treatment regimen establish condition stabilize Previous history GuillainBarré syndrome</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>tetanus</keyword>
	<keyword>pertussis</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>meningococcus</keyword>
	<keyword>diptheria</keyword>
</DOC>